Relative cost-effectiveness of long-acting injectable cabotegravir versus oral pre-exposure prophylaxis in South Africa based on the HPTN 083 and HPTN 084 trials: a modelled economic evaluation and threshold analysis-Reference-Cited by-同舟云学术

Relative cost-effectiveness of long-acting injectable cabotegravir versus oral pre-exposure prophylaxis in South Africa based on the HPTN 083 and HPTN 084 trials: a modelled economic evaluation and threshold analysis

Published:2022-12 Issue:12 Volume:9 Page:e857-e867
ISSN:2352-3018
Container-title:The Lancet HIV
language:en
Short-container-title:The Lancet HIV

Author:

Jamieson Lise,Johnson Leigh F,Nichols Brooke E,Delany-Moretlwe Sinead,Hosseinipour Mina C,Russell Colin,Meyer-Rath Gesine

Funder

National Institutes of Health

Bill and Melinda Gates Foundation

National Institute of Mental Health

USAID Egypt

National Institute on Drug Abuse

ViiV Healthcare

National Institute of Allergy and Infectious Diseases

United States Agency for International Development

Office of the Director

Publisher

Elsevier BV

Subject

Virology,Infectious Diseases,Immunology,Epidemiology

Reference30 articles.

1. Thembisa version 4.3: a model for evaluating the impact of HIV/AIDS in South Africa;Johnson,2020

2. Brief report: preventing HIV-1 infection in women using oral preexposure prophylaxis: a meta-analysis of current evidence;Hanscom;J Acquir Immune Defic Syndr,2016

3. Effectiveness and safety of oral HIV preexposure prophylaxis for all populations;Fonner;AIDS,2016

4. Southern African guidelines on the safe use of pre-exposure prophylaxis in persons at risk of acquiring HIV-1 infection;Bekker;South Afr J HIV Med,2016

5. Cabotegravir for HIV prevention in cisgender men and transgender women;Landovitz;N Engl J Med,2021

Cited by 25 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Lenacapavir to prevent HIV infection: current prices versus estimated costs of production;Journal of Antimicrobial Chemotherapy;2024-09-03

2. Health and budget impact, and price threshold for cost-effectiveness of lenacapavir for PrEP in Eastern and Southern Africa: a modeling analysis;2024-08-21

3. The long wait for long-acting HIV prevention and treatment formulations;The Lancet HIV;2024-08

4. Simple calculations of direct impact for the initial assessment of the value of primary HIV prevention interventions;2024-07-14

5. Engagement Along the PrEP Care Continuum Among Men Who Have Sex with Men in China: A Systematic Review and Meta-analysis;AIDS and Behavior;2024-06-27